|1.||Barron, Annelise E: 6 articles (07/2015 - 11/2003)|
|2.||Udugamasooriya, D Gomika: 3 articles (12/2015 - 01/2010)|
|3.||Kapoor, Rinki: 3 articles (06/2011 - 01/2011)|
|4.||Brekken, Rolf A: 2 articles (12/2015 - 01/2010)|
|5.||Seo, Jiwon: 2 articles (07/2015 - 01/2014)|
|6.||Huang, Wei: 2 articles (07/2015 - 01/2014)|
|7.||Czyzewski, Ann M: 2 articles (01/2014 - 06/2011)|
|8.||Dohm, Michelle T: 2 articles (06/2011 - 01/2011)|
|9.||Minna, John D: 1 article (12/2015)|
|10.||Matharage, Jaya M: 1 article (12/2015)|
01/01/2014 - "Several peptoids are found to be potent against a broad range of cancer cell lines at low-micromolar concentrations including cancer cells with multidrug resistance (MDR), causing cytotoxicity in a concentration-dependent manner. "
12/18/2015 - "This screen identified a peptide-peptoid hybrid called PPS1 which displayed high specific binding for HCC4017 cancer cells over HBEC30KT cells. "
12/18/2015 - "We utilized a peptidomimetic based on-bead two-color (OBTC) combinatorial cell screen that can detect differences between two cell surfaces at high accuracy by looking for beads (where each bead in the library had one peptide-peptoid hybrid on the surface) that only bound cancer but not normal cells. "
01/01/2014 - "Several cationic, amphipathic peptoids are very attractive for further development due to their high solubility, stability against protease degradation, their broad, potent cytotoxicity against cancer cells and their ability to overcome multidrug resistance. "
01/01/2011 - "Recently, a dimeric peptoid, GU40C4, was reported as a highly potent antagonist of VEGFR2 activation inhibiting angiogenesis and tumor growth in vivo. "
|2.||Huntington Disease (Huntington's Disease)
|3.||Breast Neoplasms (Breast Cancer)
01/01/2014 - "Furthermore, peptoid 1, the most potent peptoid synthesized, significantly inhibited tumor growth in a human breast cancer xenotransplantation model without any noticeable acute adverse effects in mice. "
01/01/2010 - "This study demonstrates the VEGFR2 antagonist peptoid, GU81, enhances the anti-tumor activity of doxorubicin in spontaneous murine MMTV-PyMT breast tumors."
01/01/2010 - "GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer."
02/01/1999 - "In preclinical toxicology studies CI-988, a peptoid cholecystokinin (CCK) ligand with nanomolar affinity for the CCK-B/gastrin receptor, caused gastric gland degeneration and mucosal atrophy in cynomolgus monkeys, perhaps consistent with an expected pharmacological outcome of inhibition of the trophic effect of gastrin on stomach mucosa. "
|5.||Prostatic Neoplasms (Prostate Cancer)
07/15/2015 - "Herein, we report a library of peptide-peptoid hybrid prodrugs that can be selectively activated by prostate cancer cells. "
01/01/2011 - "PET imaging evaluation using a prostate cancer xenograft (PC3) mouse model showed that (64)Cu-DOTA-GU40C4 had a prominent and steady accumulation in the VEGFR2 positive PC3 tumors (2.25 ± 0.24, 2.15 ± 0.34, and 1.90 ± 0.18 %ID/g at 1, 4, and 20 h p.i., respectively; n = 3), which is significantly higher than the control peptoid conjugate (0.3 - 0.5 %ID/g; p < 0.001 at 1, 4, and 20 h p.i.). "
|2.||Anti-Infective Agents (Microbicides)
|3.||Cholecystokinin B Receptor
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)